TI
RAPP

Trexquant Investment’s Rapport Therapeutics RAPP Stock Holding History

Trexquant Investment’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.25M Buy
53,937
+32,953
+157% +$1.21M 0.01% 1145
2026
Q1 		$657K Sell
20,984
-41,995
-67% -$1.18M ﹤0.01% 1377
2025
Q4 		$1.91M Buy
62,979
+42,460
+207% +$1.18M 0.02% 1006
2025
Q3 		$609K Buy
+20,519
New +$366K 0.01% 1276

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Trexquant Investment's RAPP Position: Q2 2026 in Review

Trexquant Investment increased its Rapport Therapeutics (RAPP) stake by 157% in Q2 2026, buying an estimated $1.21M and bringing the position to 53,937 shares worth $2.25M. The position accounts for 0.01% of the portfolio, ranked #1145.

Trexquant Investment first reported a position in RAPP in Q3 2025 and has held it in 4 quarters since. 161 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

  • Trexquant Investment held 53,937 shares of Rapport Therapeutics worth $2.25M as of Q2 2026.
  • Trexquant Investment bought 32,953 Rapport Therapeutics shares in Q2 2026, an estimated $1.21M.
  • Rapport Therapeutics made up 0.01% of Trexquant Investment's portfolio in Q2 2026, its #1145 holding.
  • Trexquant Investment first reported a position in Rapport Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 161 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on Trexquant Investment's 13F filing for Q2 2026, filed 14 Aug 2026.